Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy

Archives of Iranian Medicine

Volumn 14, Issue 4, 2011, Pages 238-243

  Shamsi Meymandi, Simin ^a   Javadi, Abdolreza ^a   Dabiri, Shahriar ^a   Shamsi Meymandi, Manzumeh ^a   Nadji, Mehrdad ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cd1a; CD20; CD3; CD68; Cutaneous leishmaniasis; Imiquimod; Meglumine antimoniate

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; IMIQUIMOD; MEGLUMINE ANTIMONATE; T6 ANTIGEN; AMINOQUINOLINE DERIVATIVE; ANTIPROTOZOAL AGENT; CD1 ANTIGEN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN; MEGLUMINE; MEGLUMINE ANTIMONIATE; ORGANOMETALLIC COMPOUND;

AGED; ARTICLE; B LYMPHOCYTE; CELL AGGREGATION; CELL INFILTRATION; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EXOCYTOSIS; FEMALE; HISTIOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; IRAN; LANGERHANS CELL; MALE; MONOTHERAPY; NEUTROPHIL COUNT; PARASITE LOAD; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SKIN LEISHMANIASIS; T LYMPHOCYTE; UPREGULATION; ADOLESCENT; ADULT; ANIMAL; DERMIS; DRUG COMBINATION; EPIDERMIS; IMMUNOLOGY; LEISHMANIA TROPICA; LYMPHOCYTE COUNT; MACROPHAGE; MIDDLE AGED; PATHOLOGY; SINGLE BLIND PROCEDURE;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; ANIMALS; ANTIGENS, CD; ANTIGENS, CD1; ANTIGENS, CD20; ANTIGENS, CD3; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIPROTOZOAL AGENTS; B-LYMPHOCYTES; CHILD; DERMIS; DRUG THERAPY, COMBINATION; EPIDERMIS; FEMALE; HUMANS; IRAN; LANGERHANS CELLS; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; LYMPHOCYTE COUNT; MACROPHAGES; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PARASITE LOAD; SINGLE-BLIND METHOD; T-LYMPHOCYTES; YOUNG ADULT;

EID: 80054967037     PISSN: 10292977     EISSN: 17353947     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Garcia LS. Diagnostic Medical Parasitology. 5th ed. Washington DC: ASM press; 2007: 192-217
2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet. 2005; 366: 1561-1577
3. Ardehali S, Hatam GR, Hosseini SMH. Isoenzyme studies in characterization of Leishmania isolated in Iran. Iran J Med Sci. 1999; 24: 8-13
4. Sharifi I., Fekri AR, Aflatonian MR, Nadim A, Nikian Y, Khamesipour A. Cutaneous leishmaniasis in primary school children in the south eastern Iran city of Bam, 1994-1995. Bull World Health Org. 1998; 76: 289-293
5. Willard RJ, Jeffcoat AM, Benson PM, Walsh DS. Cutaneous leishmaniasis in soldier from Fort Campbell, Kentucky. Returning from operation Iraqi freedom highlights diagnostic and therapeutic options. Am Acad Dermatol. 2005; 52: 977-987
6. Minodier PH, Parola PH. Cutaneous leishmaniasis treatment. Travel Med Infec Dis. 2007; 5: 150-158
7. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis. 2001; 33: 1847-1851
8. Miranda-Verastegui C, Lianos-Cuentas A, Arevalo I, Warld BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin Infect Dis. 2005; 40: 1395-1403
9. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003; 139: 1325-1332
10. Suzuki H, Wang B, Shivji GM, Toto P, Amerio P, Tomai MA, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000; 114: 135-141
11. Michalopoulos P, Yawalkar N, Brönnimann M, Kappeler A, Braathen LR. Characterization of the cellular in filtrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol. 2004; 151: 903-906
12. Barnetson R, Satchell A, Zhuang L, Slade HB, Halliday GM. Imiquimod induced regression of clinically diagnosed superficial basal cell carcinoma is associated with early in filtration by CD4 T cells and dendritic cells. Clin Exp Dermatol. 2004; 29: 639-643
13. Reiter M, Testerman T, Miller R, Weeks C, Tomai M. Cytokine induction in mice by the immunomodulator imiquimod. J Leukok Biol. 1994; 55: 234-240
14. Modabber F, Buffet PA, Torreele E, Milon G. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis. 2007; 6: 3.
15. Crawford R, Holmes D, Meymandi S. Comparative study of the efficacy of combined imiquimod 5% cream and intralesional meglumine antimoniate vs imiquimod 5% cream and intralesional meglumine anti-moniate alone for the treatment of cutaneous leishmaniasis. J Am Acad Dermatol. 2005: 52 (supp1): S118
16. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskanderi SE, Khatami A, et al. Imiquimod in combination with meglumine antimoniate for cutaneous lershmaniasis. Arch Dermatol. 2006; 142: 1575-1579
17. Darabi H, Abolhassani M, Kariminia A, Alimohammadian MH. Expansion of gamma delta T cells in patients infected with cutaneous leishmaniasis with and without glucantime therapy. Braz J Infect Dis. 2002; 6: 258-262
18. Pirmez C, Oliveira-Neto MP, Grimaldi G Jr., Savino W. Immunopathology of American cutaneous leishmaniasis. Modulation of MHC class II gene products by keratinocytes before and after glucantime therapy. Mem Inst Oswaldo Cruz. 1990; 85: 203-209
19. Mohajery M, Shamsian AA, Mahmoodi M. Tc1 cells percentage in patients with cutaneous leishmaniasis before and after treatment with Glucantim. Iran J Publ Health. 2007; 36: 55-6
20. Manna L, Reale S, Vitale F, Picillo E, Pavone LM, Gravino AE. Realtime PCR assay in Leishmania-infected dogs treated with meglumine antimoniate and allopurinol. Vet J. 2008; 177: 279-282
21. Henao HH, Osorio Y, Saravia NG, Gómez A, Travi B. Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application. Biomedica. 2004; 24: 393-402
22. DaMata JP, Sousa-Franco J, Lima-Santos J, Horta MF. Evidence of apoptosis in macrophages infected with Leishmania amazonensis and Leishmania guyanensis. Rev Inst Med Trop Sao Paulo. 2003; 45: 152-153
23. Berman B, Villa M, Ramirez C. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatolo. 2006; 5: 167-173
24. Fallah H, Fischer G, Zagarella S. Pyogenic granuloma in children: treatment with topical imiquimod. J Drugs Dermato. 2005; 4: 708-717
25. Kumar V, Abbas A, Fausto N. Pathologic Basis of Disease. 7th ed. Philadelphia: Saunders; 2005: 403-404
26. Papadopoulos EJ. Imiquimod 5% cream, 2007. Available from: URL: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM162961.pdf. [Cited 2009 Sept. 28].
27. Trevino J, Prieto VG, Hearne R, Polk A, Diwan AH. Atypical lymphocytic reaction with epidermotropism and lymphocytic vasculopathic reaction (lymphocytic vasculitis) after treatment with imiquimod. J Am Acad Dermatol. 2006; 55: 123-125.